Vincerx Pharma (VINC) Competitors $0.54 -0.03 (-4.85%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$0.55 +0.01 (+1.84%) As of 03/28/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VINC vs. BTAI, ONVO, BGXX, OMGA, CYCN, NKGN, SNOA, GTBP, SNGX, and ALZNShould you be buying Vincerx Pharma stock or one of its competitors? The main competitors of Vincerx Pharma include BioXcel Therapeutics (BTAI), Organovo (ONVO), Bright Green (BGXX), Omega Therapeutics (OMGA), Cyclerion Therapeutics (CYCN), NKGen Biotech (NKGN), Sonoma Pharmaceuticals (SNOA), GT Biopharma (GTBP), Soligenix (SNGX), and Alzamend Neuro (ALZN). These companies are all part of the "pharmaceutical products" industry. Vincerx Pharma vs. BioXcel Therapeutics Organovo Bright Green Omega Therapeutics Cyclerion Therapeutics NKGen Biotech Sonoma Pharmaceuticals GT Biopharma Soligenix Alzamend Neuro Vincerx Pharma (NASDAQ:VINC) and BioXcel Therapeutics (NASDAQ:BTAI) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, community ranking, media sentiment, risk, dividends and valuation. Which has preferable valuation and earnings, VINC or BTAI? Vincerx Pharma has higher earnings, but lower revenue than BioXcel Therapeutics. BioXcel Therapeutics is trading at a lower price-to-earnings ratio than Vincerx Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVincerx PharmaN/AN/A-$40.16M-$20.60-0.03BioXcel Therapeutics$2.28M2.99-$179.05M-$25.97-0.08 Which has more risk & volatility, VINC or BTAI? Vincerx Pharma has a beta of 1.43, meaning that its stock price is 43% more volatile than the S&P 500. Comparatively, BioXcel Therapeutics has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500. Does the MarketBeat Community favor VINC or BTAI? BioXcel Therapeutics received 226 more outperform votes than Vincerx Pharma when rated by MarketBeat users. Likewise, 67.67% of users gave BioXcel Therapeutics an outperform vote while only 65.63% of users gave Vincerx Pharma an outperform vote. CompanyUnderperformOutperformVincerx PharmaOutperform Votes2165.63% Underperform Votes1134.38% BioXcel TherapeuticsOutperform Votes24767.67% Underperform Votes11832.33% Do insiders & institutionals have more ownership in VINC or BTAI? 44.0% of Vincerx Pharma shares are owned by institutional investors. Comparatively, 30.7% of BioXcel Therapeutics shares are owned by institutional investors. 15.6% of Vincerx Pharma shares are owned by company insiders. Comparatively, 21.2% of BioXcel Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts recommend VINC or BTAI? Vincerx Pharma currently has a consensus target price of $40.00, indicating a potential upside of 7,319.77%. BioXcel Therapeutics has a consensus target price of $42.60, indicating a potential upside of 1,909.43%. Given Vincerx Pharma's stronger consensus rating and higher probable upside, equities analysts plainly believe Vincerx Pharma is more favorable than BioXcel Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vincerx Pharma 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00BioXcel Therapeutics 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.67 Does the media refer more to VINC or BTAI? In the previous week, BioXcel Therapeutics had 4 more articles in the media than Vincerx Pharma. MarketBeat recorded 7 mentions for BioXcel Therapeutics and 3 mentions for Vincerx Pharma. Vincerx Pharma's average media sentiment score of 1.28 beat BioXcel Therapeutics' score of 0.65 indicating that Vincerx Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vincerx Pharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioXcel Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Is VINC or BTAI more profitable? Vincerx Pharma has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -3,119.33%. BioXcel Therapeutics' return on equity of 0.00% beat Vincerx Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Vincerx PharmaN/A -248.33% -132.73% BioXcel Therapeutics -3,119.33%N/A -105.04% SummaryVincerx Pharma and BioXcel Therapeutics tied by winning 9 of the 18 factors compared between the two stocks. Remove Ads Get Vincerx Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for VINC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VINC vs. The Competition Export to ExcelMetricVincerx PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.21M$6.90B$5.63B$7.84BDividend YieldN/A2.77%5.33%4.01%P/E Ratio-0.037.2623.5518.73Price / SalesN/A218.62388.2390.77Price / CashN/A65.6738.1734.64Price / Book0.056.386.894.23Net Income-$40.16M$142.34M$3.20B$247.47M7 Day Performance-16.81%-5.15%-3.06%-2.29%1 Month Performance-50.54%-7.55%1.51%-5.81%1 Year Performance-99.47%-11.06%9.37%-0.96% Vincerx Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VINCVincerx Pharma3.6717 of 5 stars$0.54-4.9%$40.00+7,319.8%-99.5%$1.21MN/A-0.0360Upcoming EarningsShort Interest ↓Positive NewsGap DownBTAIBioXcel Therapeutics4.6588 of 5 stars$2.28+7.0%$37.00+1,522.8%-95.3%$7.31M$2.28M-0.0790Earnings ReportShort Interest ↓News CoverageGap DownONVOOrganovo1.0045 of 5 stars$0.43+0.4%N/A-80.5%$7.31M$122,000.00-0.5020Analyst ForecastStock SplitShort Interest ↓News CoverageBGXXBright GreenN/A$0.04+10.3%N/A-75.4%$7.17MN/A-0.632Gap DownOMGAOmega Therapeutics1.9358 of 5 stars$0.13-21.8%$9.20+7,260.0%-96.6%$6.92M$8.10M-0.09120Gap UpCYCNCyclerion Therapeutics2.3119 of 5 stars$2.55+0.8%N/A-19.7%$6.91M$2M-2.0930Short Interest ↓NKGNNKGen BiotechN/A$0.15-12.0%N/A-91.4%$6.72M$80,000.00-0.03N/AGap DownSNOASonoma Pharmaceuticals0.3704 of 5 stars$3.86+9.3%N/A+1,349.2%$6.24M$13.97M-0.96180Short Interest ↑News CoverageGap DownGTBPGT Biopharma3.4561 of 5 stars$2.40-6.3%$11.00+358.3%-45.8%$6.09MN/A-0.348Short Interest ↓News CoverageSNGXSoligenix1.5072 of 5 stars$2.36+2.6%N/A-77.0%$5.92M$840,000.00-0.3120Earnings ReportShort Interest ↓Analyst RevisionNews CoverageGap DownALZNAlzamend Neuro3.4493 of 5 stars$0.89+32.1%$20.00+2,134.9%-89.4%$5.90MN/A0.004Short Interest ↓News CoverageGap Up Remove Ads Related Companies and Tools Related Companies BTAI Competitors ONVO Competitors BGXX Competitors OMGA Competitors CYCN Competitors NKGN Competitors SNOA Competitors GTBP Competitors SNGX Competitors ALZN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VINC) was last updated on 3/30/2025 by MarketBeat.com Staff From Our PartnersNew Pick (93% history of rising by May 8)We just posted a new recommendation. Keep in mind: You could have boosted the Netflix trade we issued to the p...InvestorPlace | SponsoredTrump's 100-Day Plan Triggers Global RetaliationIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredPartner with Elon Musk on Project Colossus… Before May 1stEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredHuge Elon-backed AI rollout begins – buy these nine stocksIf you suspect Elon Musk has an ulterior motive for coming to Washington, D.C.... You're 100% correct. ...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vincerx Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vincerx Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VINC Stock Free VINC Stock Alerts